Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL)

被引：1
|
作者：
Li, He [1 ]
Zhang, Wanhua [1 ]
Yi, Dongni [1 ]
Ye, Yuanxin [2 ]
Xiao, Xueqiu [3 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Hematol, Hematol Res Lab, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China
[3] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 04期
关键词：
CHRONIC MYELOID-LEUKEMIA; BCR-ABL; CLINICAL IMPACT; IMATINIB; RESISTANT; THERAPY;
D O I：
10.1080/10428194.2016.1225205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1005 / 1007
页数：3
相关论文
共 50 条
  • [21] Ponatinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Shamroe, Caitlin L.
    Comeau, Jill M.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1540 - 1546
  • [22] Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel
    Aoe, M.
    Ishida, H.
    Matsubara, T.
    Karakawa, S.
    Kawaguchi, H.
    Fujiwara, K.
    Kanamitsu, K.
    Washio, K.
    Okada, K.
    Shibakura, M.
    Shimada, A.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (04) : 427 - 436
  • [23] The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment
    Thomas, Xavier
    Heiblig, Mael
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (11) : 1061 - 1070
  • [24] Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ottmann, O. G.
    Larson, R. A.
    Kantarjian, H. M.
    le Coutre, P. D.
    Baccarani, M.
    Hochhaus, A.
    Kim, D. W.
    Fan, X.
    Novick, S.
    Giles, F. J.
    LEUKEMIA, 2013, 27 (06) : 1411 - 1413
  • [25] The impacts ofBCR-ABL1mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation
    Tachibana, Takayoshi
    Najima, Yuho
    Akahoshi, Yu
    Hirabayashi, Shigeki
    Harada, Kaito
    Doki, Noriko
    Uchida, Naoyuki
    Fukuda, Takahiro
    Sawa, Masashi
    Ogata, Masao
    Takada, Satoru
    Tanaka, Masatsugu
    Matsuhashi, Yoshiko
    Tanaka, Junji
    Onizuka, Makoto
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Kako, Shinichi
    ANNALS OF HEMATOLOGY, 2020, 99 (10) : 2393 - 2404
  • [26] Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Cerchione, Claudio
    Locatelli, Franco
    Martinelli, Giovanni
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [27] Droplet digital polymerase chain reaction improves the detection of BCR-ABL1 kinase domain mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Wan, Li
    Ma, Jiao
    Gong, Xiaoyuan
    Li, Qinghua
    Wang, Ying
    Wei, Hui
    Wang, Jianxiang
    Xiao, Zhijian
    Mi, Yingchang
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 (04) : 528 - 532
  • [28] Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Piccaluga, Pier Paolo
    Paolini, Stefania
    Martinelli, Giovanni
    CANCER, 2007, 110 (06) : 1178 - 1186
  • [29] Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant
    Samra, Bachar
    Kantarjian, Hagop M.
    Sasaki, Koji
    Alotaibi, Ahmad S.
    Konopleva, Marina
    O'Brien, Susan
    Ferrajoli, Alessandra
    Garris, Rebecca
    Nunez, Cesar A.
    Kadia, Tapan M.
    Short, Nicholas J.
    Jabbour, Elias
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 285 - 292
  • [30] Therapy of Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) with inhibitor of the abl tyrosinkinase (Glivec)
    Ottmann, OG
    Wassmann, B
    Hoelzer, D
    MEDIZINISCHE KLINIK, 2002, 97 : 16 - 21
12345